Although studies thus far have not demonstrated an increased risk profile when GLP-1 agonists are used in a population of patients with advanced MASH, there are questions about these therapies’ effect on muscle loss and whether this muscle loss might precipitate liver decompensation. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.